Maxim Upgrades Indaptus Therapeutics To Buy

Loading...
Loading...
  • Maxim analyst has upgraded Indaptus Therapeutics Inc INDP to Buy from Hold with a $16 price target, an upside of over 100%.
  • Analyst Jason McCarthy says, Indaptus is leveraging the ability of attenuated, non-pathogenic gram-negative bacteria to stimulate both innate and adaptive immune responses for oncology indications and infectious diseases.
  • In a research note, the analyst tells investors that it is also building on the initial immune therapy, Coley's toxins, with a "modernized, safer, and more effective approach." 
  • McCarthy further states that the key for Indaptus is its cash runway, an experienced management team, and a program in Decoy20 that could potentially be paired with several existing cancer therapeutics.
  • Related: Why Are Indaptus Therapeutics Shares Shooting Higher On Wednesday?
  • Price Action: INDP shares are up 3.45% at $7.80 during the market session on the last check Tuesday.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsUpgradesHealth CarePrice TargetAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...